12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sativex regulatory update

GW Pharma submitted a regulatory application in France for Sativex to treat spasticity due to multiple sclerosis (MS) under the European mutual recognition procedure, with the U.K. acting as the reference member state. The company said the application follows a June decree by the...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >